Last C$12.15 CAD
Change Today -0.01 / -0.08%
Volume 3.1K
NVC On Other Exchanges
As of 11:19 AM 03/3/15 All times are local (Market data is delayed by at least 15 minutes).

neovasc inc (NVC) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/30/15 - C$12.75
52 Week Low
08/26/14 - C$4.96
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for NEOVASC INC (NVC)

Related News

No related news articles were found.

neovasc inc (NVC) Related Businessweek News

No Related Businessweek News Found

neovasc inc (NVC) Details

Neovasc Inc., a specialty medical device company, develops, manufactures, and markets cardiovascular products worldwide. Its products include the Neovasc Reducer for the treatment of refractory angina; and Tiara technology in development for the transcatheter treatment of mitral valve disease. The company also develops and manufactures the PeriPatch, a line of biological tissue products for use in third-party medical products, including transcatheter heart valves. In addition, the company provides a range of custom Peripatch products to industry customers for incorporation into their own products; and consulting and original equipment manufacturing services to other medical device companies. Further, it offers pericardial tissue processing, vascular product development, design, and manufacturing solutions to industry partners. The company was formerly known as Medical Ventures Corp. and changed its name to Neovasc Inc. in July 2008. Neovasc Inc. was incorporated in 2000 and is headquartered in Richmond, Canada.

119 Employees
Last Reported Date: 05/13/14
Founded in 2000

neovasc inc (NVC) Top Compensated Officers

Chief Executive Officer and Non-Independent D...
Total Annual Compensation: C$302.5K
Chief Financial Officer and Corporate Secreta...
Total Annual Compensation: C$242.0K
Chief Operating Officer and President of Neov...
Total Annual Compensation: C$192.5K
Vice President of Research and Development
Total Annual Compensation: C$174.9K
Compensation as of Fiscal Year 2013.

neovasc inc (NVC) Key Developments

Neovasc Inc. Announces the Final Results from its COSIRA Study

Neovasc Inc. announced that the final results from its COSIRA study assessing the efficacy and safety of the Neovasc Reducer for treatment of Refractory Angina. Refractory Angina is a debilitating disease involving chronic chest pain and affecting millions of patients worldwide who have limited treatment options. The COSIRA study met its primary endpoint, demonstrating the efficacy of the Reducer in relieving angina symptoms in these patients. The Canadian Cardiovascular Society ("CCS") angina grading scale is a four-class functional classification that is widely used to characterize the severity of angina symptoms and disability. Only patients with severe angina, CCS Class 3 or 4, were enrolled in the COSIRA trial. The COSIRA data demonstrates that patients treated with the Reducer achieved a statistically significant improvement in CCS angina grading scale scores (two classes or better) compared to those patients in the sham control arm, (p-value = 0.024). Patients treated with the Reducer were 2.3 times more likely to see an improvement of two classes or better in CCS score than the sham control arm. The analysis also demonstrated that patients treated with the Reducer showed a statistically significant improvement of one or more CCS classes compared to the sham control patients (p-value = 0.003). The study also demonstrated a 96.2% technical success rate and a 100% procedural success rate for Reducer implantation.

Neovasc Inc. Presents at Leerink's Global Healthcare Conference, Feb-11-2015 10:40 AM

Neovasc Inc. Presents at Leerink's Global Healthcare Conference, Feb-11-2015 10:40 AM. Venue: Waldorf Astoria New York, New York, New York, United States. Speakers: Alexei J. Marko, Chief Executive Officer and Non-Independent Director, Chris Clark, Chief Financial Officer and Corporate Secretary.

Neovasc Inc. Announces Treatment of First Patient in TIARA-I Clinical Trial

Neovasc Inc. announced that the first patient has been enrolled in the European arm of its TIARA-I Early Feasibility Trial, a multinational, multicenter trial being conducted at centers in the US, Europe and Canada to assess the safety and performance of Neovasc's Tiara(TM) mitral valve system and implantation procedure in high-risk surgical patients suffering from severe mitral regurgitation ("MR"). Severe MR is a critical condition that affects millions of patients and, if left untreated, can lead to heart failure or death. The first patient was enrolled by Dr. Stefan Verheye, at the Antwerp Cardiovascular Center /ZNA Middelheim, Belgium. The Tiara valve implantation was completed via a minimally invasive, transapical, transcatheter approach, resulting in elimination of the patient's MR without leaks or other complications. To date, recovery of the patient has been uneventful. TIARA-I has received institutional review board (IRB) approval from the first of the participating US medical centers and anticipates US implantations of Tiara to begin in the coming months. It is expected that additional European and Canadian sites will begin enrolling patients in early 2015. The company also confirmed that in November Tiara was implanted in a fourth Canadian patient at St. Paul's Hospital in Vancouver Canada under Special Access (compassionate use) regulatory approval. This implantation was completed uneventfully and resulted in a well-functioning prosthetic valve with no residual MR, leaks or other complications. The patient was discharged home on day five following implantation and their recovery has been uneventful to date.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NVC:CN C$12.15 CAD -0.01

NVC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Edwards Lifesciences Corp $135.18 USD -0.67
St Jude Medical Inc $67.80 USD -0.56
View Industry Companies

Industry Analysis


Industry Average

Valuation NVC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 37.3x
Price/Book 23.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 44.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NEOVASC INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at